Switching between biological agents

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  van Vollenhoven, Ronald F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adalimumab; Biologicals; Etanercept; Inflammatory arthritides; Infliximab; Longitudinal studies; Switching

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; INFUSION; INFUSION REACTION; LIVER TOXICITY; NOSE CONGESTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHINORRHEA; SIDE EFFECT; SMELLING DISORDER; CLINICAL OUTCOME; CORRELATION COEFFICIENT; CROHN DISEASE; DAS28; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HYPERSENSITIVITY; JUVENILE RHEUMATOID ARTHRITIS; NOSE OBSTRUCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4944267708     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. LIPSKY PE, VAN DER HEIJDE DM, St CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
2. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (pg75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
3. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
4. KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207-12
5. HUSNI ME, MAIER AL, MEASE PJ et al.: Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171-6.
6. HOCHBERG MC, TRACY JK, HAWKINS-HOLT M, FLORES RH: Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 2): ii 13-6.
7. GEBOREK P, CRNKIC M, PETERSSON IF et al.: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
8. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
9. RUTGEERTS P, FEAGAN BG, LICHTENSTEIN GR et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
10. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
11. HARAOUI B: Is there a rationale for switching from one anti-tumor necrosis factor agent to another ? J Rheumatol 2004; 31: 1021-2.
12. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
13. SMEETS TJ, KRAAN MC, VAN LOON ME, TAK PP: Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 2155-62.
14. CATRINA AI, TROLLMO C, LAMPA J et al.: Anti TNF therapy with both infliximab and etanercept induces apoptosis in rheumatoid arthritis synovium. (Abstract) Eular 2004.
15. BROCQ O, PLUBEL Y, BREUIL V et al.: Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF-alpha. Presse Med 2002; 31: 1836-9.
16. ANG HT, HELFGOTT S: Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis ? J Rheumatol 2003; 30: 2315-8.
17. SANMARTI R, GOMEZ-PUERTA JA, RODRIGUEZ-CROS JR, ALBALADEJO C, MUNOZ-GOMEZ J, CANETE JD: Etanercept in rheumatoid arthritis patients with a poor therapeutic response to Infliximab. Med Clin (Barc) 2004; 122: 321-4.
18. GOMEZ-PUERTA JA, SANMARTI R, RODRIGUEZ-CROS JR, CANETE JD: Etanercept is effective in patients with rheumatoid arthritis with no response to infliximalb therapy. Ann Rheum Dis 2004; 63: 896 (letter).
19. HANSEN KE, HILDEBRAND JP, GENOVESE MC et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1098-102.
20. YAZICI Y, ERKAN D: Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed ? Ann Rheum Dis 2004; 63: 607-8 (letter).
21. FAVALLI EG, ARREGHINI M, ARNOLDI C et al.: Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004; 51: 301-2 (letter).
22. VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
23. PREVOO MLL, VAN'T HOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995; 38: 44-8.
24. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
25. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid. Arthritis Rheum 1995; 38: 727-35.
26. WICK MC, LINDBLAD S, KLARESKOG L, VAN VOLLENHOVEN RF: Adalimumab (Humira) restores clinical response in patients who have lost response to infliximab (Remicade) or etanercept (Enbrel): data from the STURE registry. (Abstract) Eular 2004.